Future studies are hence necessary to determine whether the selective targeting of altered pathways of fAD mutant neurons is sufficient for effectively managing the progression of neuropathological changes in AD and the clinical features of the disease. The gene discussed is PSEN1; the disease is Alzheimer disease.